Abstract:Pituitary tumors are very complex and heterogeneous and have a very wide range of proliferative and aggressive behaviors, and how to define and classify these tumors remains controversial. This review summarizes the epidemiology and progress in the classification and definition of pituitary tumors, as well as controversial issues. Based on the results of radiologic and autopsy studies, the prevalence of pituitary tumors has recently increased significantly. However, the majority of pituitary tumors are incidentally discovered and asymptomatic, and such tumors are called pituitary incidentalomas. Most of these incidentalomas do not induce symptoms, remain stable in size, and do not need treatment. The recent revised classification strategies mainly depend on immunohistochemistry (IHC) to detect pituitary hormones and pituitary transcription factors; therefore, the accuracy of diagnosing pituitary tumors has improved. Although new classification strategies and definitions for pituitary tumors have been presented, there are still some controversies. The term pituitary neuroendocrine tumor (PitNET) was proposed by the International Pituitary Pathology Club, and this terminology can encompass the unpredictable malignant behavior seen in the subset of aggressive pituitary adenomas (PAs). However, some endocrinologists who oppose this change in terminology have argued that the use of tumor in the terminology is misleading, as it gives PAs a harmful connotation when the majority are not aggressive. Such terminology may add new ambiguity to the origin of PAs and unnecessary anxiety and frustration for the majority of patients with benign PAs. The classification of aggressive PAs mainly relies on subjective judgment of clinical behavior and lacks objective biomarkers and unified diagnostic criteria. However, the term "refractory" could more accurately represent the characteristics of these tumors, including their clinical behaviors, radiological features, and pathologic characteristics. Moreover, the diagnostic criteria for refractory PAs are stricter, more objective, and more accurate than those for aggressive PAs. Early identification of patients with these tumors through recognition and increased awareness of the definition of refractory PAs will encourage the early use of aggressive therapeutic strategies.

Research progress on the role of the Wnt signaling pathway in pituitary adenoma

Potential biomarkers and lncRNA-mRNA regulatory networks in invasive growth hormone-secreting pituitary adenomas

Human Pituitary Adenoma Proteomics: New Progresses And Perspectives

Emerging Roles of miRNA, lncRNA, circRNA, and Their Cross-Talk in Pituitary Adenoma

Enhanced EPR Effects by Tumour Stromal Cell Mimicking Nanoplatform on Invasive Pituitary Adenoma

Autophagy and Pituitary Adenoma

Exosomal RNAs in the development and treatment of pituitary adenomas

The Expression Profile of PD-L1 and CD8(+) Lymphocyte in Pituitary Adenomas Indicating for Immunotherapy

Biomarker Discovery For Immunotherapy Of Pituitary Adenomas: Enhanced Robustness And Prediction Ability By Modern Computational Tools

Pathogenesis, clinical features, and treatment of plurihormonal pituitary adenoma

Progress of immune checkpoint inhibitors in aggressive pituitary adenomas

Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions

Targeting Aggressive Pituitary Adenomas at the Molecular Level—A Review

The MAPK Pathway-Based Drug Therapeutic Targets in Pituitary Adenomas

Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors

EPCO-28. SINGLE-CELL RNA SEQUENCING IDENTIFIES INTRATUMORAL HETEROGENEITY AND ACTIVATION OF PRO-INVASIVE PATHWAYS IN NON-FUNCTIONING PITUITARY ADENOMAS

Approaches based on natural products and miRNAs in pituitary adenomas: unveiling therapeutic intervention

BRD4 As a Therapeutic Target for Nonfunctioning and Growth Hormone Pituitary Adenoma.

Research status and prospects of pituitary adenomas in conjunction with neurological and psychiatric disorders and the tumor microenvironment

Clinical and Pathologic Characteristics Predicted the Postoperative Recurrence and Progression of Pituitary Adenoma: A Retrospective Study with 10 Years Follow-Up

How To Classify And Define Pituitary Tumors: Recent Advances And Current Controversies